Related Experiment Videos
Combined decrease of postheparin-diamine oxidase (histaminase) and postheparin-lipoproteinlipase in inflammatory
Klinische Wochenschrift
|February 15, 1977
Summary
Heparin administration in patients with inflammatory diseases significantly reduced the release of diamine oxidase (DAO) and lipoprotein lipase (LL). This decrease in postheparin enzymes suggests a systemic effect of inflammation on enzyme metabolism.
Area of Science:
- Biochemistry
- Enzymology
- Clinical Medicine
Background:
- Diamine oxidase (DAO) is crucial for histamine metabolism, while lipoprotein lipase (LL) is key in lipid metabolism.
- Heparin administration typically increases plasma levels of DAO and LL by releasing them from tissues.
Purpose of the Study:
- To investigate the plasma levels of DAO and LL after heparin administration in patients with inflammatory diseases.
- To assess the correlation between the release of these enzymes and disease activity or other biochemical markers.
Main Methods:
- Studied 30 patients with 20 different inflammatory diseases.
- Administered heparin (200 U/kg, i.v.) and measured postheparin diamine oxidase (PHD) and postheparin lipoproteinlipase (PHLA) levels.
- Correlated enzyme levels with plasma insulin, triglycerides, serum glutamic pyruvic transaminase, and C-reactive protein (CRP).
Main Results:
- A marked decrease in PHD and PHLA release was observed in all patients.
- A significant positive correlation (r=0.843) was found between PHD and PHLA release.
- Decreased PHD/PHLA levels were more sensitive indicators of inflammation than SGPT in hepatitis or CRP in kidney disease.
Conclusions:
- Inflammatory diseases significantly impair the heparin-induced release of DAO and LL.
- The reduced release of PHD and PHLA is a sensitive marker for inflammatory conditions.
- Inflammation-dependent mechanisms, beyond hormonal regulation, likely affect PHLA levels.